Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 292

The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.

Diffuse large B-cell lymphoma: R-CHOP failure—what to do?

Open access
Coiffier, Bertrand, Sarkozy, Clémentine·2016·Hematology
DOI 10.1182/asheducation-2016.1.366
Open this paper in CoChat — free account

Abstract

Although rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard treatment for patients with diffuse large B-cell lymphoma (DLBCL), ∼30% to 50% of patients are not cured by this treatment, depending on disease stage or prognostic index. Among patients for whom R-CHOP therapy fails, 20% suffer from primary refractory disease (progress during or right after treatment) whereas 30% relapse after achieving complete remission (CR). Currently, there is no good definition enabling us to identify these 2 groups upon diagnosis. Most of the refractory patients exhibit double-hit lymphoma (MYC-BCL2 rearrangement) or double-protein-expression lymphoma (MYC-BCL2 hyperexpression) which have a more aggressive clinical picture. New strategies are currently being explored to obtain better CR rates and fewer relapses. Although young relapsing patients are treated with high-dose therapy followed by autologous transplant, there is an unmet need for better salvage regimens in this setting. To prevent relapse, maintenance therapy with immunomodulatory agents such as lenalidomide is currently undergoing investigation. New drugs will most likely be introduced over the next few years and will probably be different for relapsing and refractory patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/asheducation-2016.1.366

Cites

111 of 111 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 111 references

Research works printed but not linked: 48

  1. Xu-Monette, 2015, Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP, Mod Pathol, 28, 1555, 10.1038/modpathol.2015.118 · doi:10.1038/modpathol.2015.118
  2. Caponetti, 2015, Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome, Leuk Lymphoma, 56, 3082, 10.3109/10428194.2015.1034699 · doi:10.3109/10428194.2015.1034699
  3. Savage, 2016, Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL, Blood, 127, 2182, 10.1182/blood-2015-10-676700 · doi:10.1182/blood-2015-10-676700
  4. Cuccuini, 2012, MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation, Blood, 119, 4619, 10.1182/blood-2012-01-406033 · doi:10.1182/blood-2012-01-406033
  5. Oki, 2014, Double hit lymphoma: the MD Anderson Cancer Center clinical experience, Br J Haematol, 166, 891, 10.1111/bjh.12982 · doi:10.1111/bjh.12982
  6. Puvvada, 2016, Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704, Br J Haematol, 174, 686, 10.1111/bjh.14100 · doi:10.1111/bjh.14100
  7. Mounier, 2012, Relapses, treatments and new drugs, Best Pract Res Clin Haematol, 25, 49, 10.1016/j.beha.2012.01.002 · doi:10.1016/j.beha.2012.01.002
  8. Sauter, 2015, Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma, Blood, 125, 2579, 10.1182/blood-2014-10-606939 · doi:10.1182/blood-2014-10-606939
  9. Witzig, 2016, PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL) [abstract], J Clin Oncol, 34, 10.1200/JCO.2016.34.15_suppl.7506 · doi:10.1200/jco.2016.34.15_suppl.7506
  10. Friedberg, 2014, R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433, Br J Haematol, 166, 382, 10.1111/bjh.12906 · doi:10.1111/bjh.12906
  11. Witzig, 2015, A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402, Br J Haematol, 170, 679, 10.1111/bjh.13493 · doi:10.1111/bjh.13493
  12. Bielska, 2015, Human leukocyte antigen-G polymorphisms influence the clinical outcome in diffuse large B-cell lymphoma, Genes Chromosomes Cancer, 54, 185, 10.1002/gcc.22235 · doi:10.1002/gcc.22235
  13. Hasselblom, 2010, High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy, Br J Haematol, 149, 560, 10.1111/j.1365-2141.2010.08123.x · doi:10.1111/j.1365-2141.2010.08123.x
  14. Alinari, 2016, De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort, Am J Hematol, 91, 395, 10.1002/ajh.24299 · doi:10.1002/ajh.24299
  15. Adams, 2015, Prognostic value of tumor necrosis at CT in diffuse large B-cell lymphoma, Eur J Radiol, 84, 372, 10.1016/j.ejrad.2014.12.009 · doi:10.1016/j.ejrad.2014.12.009
  16. Gaudio, 2011, High Ki67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab, Acta Haematol, 126, 44, 10.1159/000324206 · doi:10.1159/000324206
  17. Goto, 2012, Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens, Ann Hematol, 91, 705, 10.1007/s00277-011-1363-4 · doi:10.1007/s00277-011-1363-4
  18. Yamauchi, 2012, Early relapse is associated with high serum soluble interleukin-2 receptor after the sixth cycle of R-CHOP chemotherapy in patients with advanced diffuse large B-cell lymphoma, Anticancer Res, 32, 5051
  19. Yuan, 2016, Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients, Oncol Lett, 11, 423, 10.3892/ol.2015.3866 · doi:10.3892/ol.2015.3866
  20. Arima, 2013, Impact of occult bone marrow involvement on the outcome of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone therapy for diffuse large B-cell lymphoma, Leuk Lymphoma, 54, 2645, 10.3109/10428194.2013.788697 · doi:10.3109/10428194.2013.788697
  21. Goto, 2012, Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone, Leuk Lymphoma, 53, 1494, 10.3109/10428194.2012.660627 · doi:10.3109/10428194.2012.660627
  22. Goto, 2011, Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens, Eur J Haematol, 87, 217, 10.1111/j.1600-0609.2011.01649.x · doi:10.1111/j.1600-0609.2011.01649.x
  23. Xu-Monette, 2016, Clinical and biologic significance of MYC genetic mutations in de novo diffuse large B-cell lymphoma, Clin Cancer Res, 22, 3593, 10.1158/1078-0432.CCR-15-2296 · DOI
  24. Hao, 2015, The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma, PLoS One, 10, e0126615, 10.1371/journal.pone.0126615 · doi:10.1371/journal.pone.0126615
  25. Higashi, 2016, Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma, Leuk Lymphoma, 57, 161, 10.3109/10428194.2015.1038708 · doi:10.3109/10428194.2015.1038708
  26. Hedström, 2013, Low expression of microRNA-129-5p predicts poor clinical outcome in diffuse large B cell lymphoma (DLBCL), Int J Hematol, 97, 465, 10.1007/s12185-013-1303-2 · doi:10.1007/s12185-013-1303-2
  27. Jardin, 2013, Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma, Leuk Lymphoma, 54, 1898, 10.3109/10428194.2013.767456 · doi:10.3109/10428194.2013.767456
  28. Jin, 2012, Homozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP, J Hematol Oncol, 5, 51, 10.1186/1756-8722-5-51 · doi:10.1186/1756-8722-5-51
  29. Koh, 2013, Receptor tyrosine kinases MET and RON as prognostic factors in diffuse large B-cell lymphoma patients receiving R-CHOP, Cancer Sci, 104, 1245, 10.1111/cas.12215 · doi:10.1111/cas.12215
  30. Jung, 2012, Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: results from a prospective cohort study, Ann Hematol, 91, 1747, 10.1007/s00277-012-1516-0 · doi:10.1007/s00277-012-1516-0
  31. Markovic, 2012, Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL), Med Oncol, 29, 3515, 10.1007/s12032-012-0232-x · doi:10.1007/s12032-012-0232-x
  32. Choi, 2016, High expression of Bcl-2 predicts poor outcome in diffuse large B-cell lymphoma patients with low international prognostic index receiving R-CHOP chemotherapy, Int J Hematol, 103, 210, 10.1007/s12185-015-1911-0 · doi:10.1007/s12185-015-1911-0
  33. Miyashita, Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy [published online ahead of print 29 August, 2015], Leuk Res
  34. Nakamura, 2013, Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen, Eur J Haematol, 91, 322, 10.1111/ejh.12139 · doi:10.1111/ejh.12139
  35. Rossi, 2011, The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma, Blood, 117, 2405, 10.1182/blood-2010-07-296244 · doi:10.1182/blood-2010-07-296244
  36. Ni, 2015, Low expression of miRNA-224 predicts poor clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP, Biomarkers, 20, 253, 10.3109/1354750X.2015.1068855 · doi:10.3109/1354750x.2015.1068855
  37. Wong, 2015, Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP, Exp Mol Pathol, 99, 537, 10.1016/j.yexmp.2015.08.019 · doi:10.1016/j.yexmp.2015.08.019
  38. Yıldırım, 2015, The role of gender in patients with diffuse large B cell lymphoma treated with rituximab-containing regimens: a meta-analysis, Arch Med Sci, 11, 708, 10.5114/aoms.2015.53289 · doi:10.5114/aoms.2015.53289
  39. Choi, 2016, Prognostic implication of semi-quantitative immunohistochemical assessment of CD20 expression in diffuse large B-cell lymphoma, J Pathol Transl Med, 50, 96, 10.4132/jptm.2016.01.12 · doi:10.4132/jptm.2016.01.12
  40. Ageberg, 2013, The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death, Am J Transl Res, 5, 170
  41. Brander, 2013, Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma, Leuk Lymphoma, 54, 2627, 10.3109/10428194.2013.784969 · doi:10.3109/10428194.2013.784969
  42. Buckstein, 2011, Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group, Leuk Lymphoma, 52, 833, 10.3109/10428194.2011.555892 · doi:10.3109/10428194.2011.555892
  43. Coiffier, 2016, A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma, Br J Haematol, 173, 722, 10.1111/bjh.13992 · doi:10.1111/bjh.13992
  44. Morschhauser, 2013, Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study, J Clin Oncol, 31, 2912, 10.1200/JCO.2012.46.9585 · DOI · Paper page
  45. Evens, 2013, A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas, Br J Haematol, 163, 55, 10.1111/bjh.12488 · doi:10.1111/bjh.12488
  46. Fayad, 2015, Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial, Leuk Lymphoma, 56, 2569, 10.3109/10428194.2015.1007504 · doi:10.3109/10428194.2015.1007504
  47. Mahadevan, 2014, Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2, PLoS One, 9, e95184, 10.1371/journal.pone.0095184 · doi:10.1371/journal.pone.0095184
  48. Matsumoto, A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy [published online ahead of print 21 March 2016], Hematol Oncol

Cited by

See all 292

Metadata

Authors
Coiffier, B., & Sarkozy, C.
Venue
Hematology
Publisher
American Society of Hematology
Published
2016-12-02
Volume
2016
Issue
1
Pages
366-378
ISSN
  • 1520-4383 (ISSN-L)
  • 1520-4391
DOI
10.1182/asheducation-2016.1.366
OpenAlex
W2559431510
Cited by
292
References
111
FWCI
7.30
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diffuse large B-cell lymphoma: R-CHOP failure—what to do? https://app.cochat.ai/papers/10.1182/asheducation-2016.1.366
The paper
Coiffier, B., & Sarkozy, C. (2016). Diffuse large B-cell lymphoma: R-CHOP failure—what to do? Hematology. https://doi.org/10.1182/asheducation-2016.1.366

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.